# Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers

> **NCT02038842** · PHASE1,PHASE2 · COMPLETED · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 92 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **BIOLOGICAL:** LIPO-5
- **BIOLOGICAL:** MVA HIV-B (MVATG17401)
- **BIOLOGICAL:** GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots

## Key facts

- **NCT ID:** NCT02038842
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-10
- **Final completion:** 2016-03
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02038842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02038842, "Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02038842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*